A novel site of antibiotic action in the ribosome: Interaction of evernimicin with the large ribosomal subunit

被引:80
作者
Belova, L
Tenson, T
Xiong, LQ
McNicholas, PM
Mankin, AS
机构
[1] Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA
[2] Univ Tartu, Inst Mol & Cell Biol, EE-51010 Tartu, Estonia
[3] Schering Plough Corp, Inst Res, Kenilworth, NJ 07033 USA
关键词
rRNA; ribosomal protein; antibiotics; L16; drug resistance;
D O I
10.1073/pnas.071527498
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Evernimicin (Evn), an oligosaccharide antibiotic, interacts with the large ribosomal subunit and inhibits bacterial protein synthesis. RNA probing demonstrated that the drug protects a specific set of nucleotides in the loops of hairpins 89 and 91 of 23S rRNA in bacterial and archaeal ribosomes. Spontaneous Evn-resistant mutants of Halobacterium halobium contained mutations in hairpins 89 and 91 of 23S rRNA, In the ribosome tertiary structure, rRNA residues involved in interaction with the drug form a tight cluster that delineates the drug-binding site. Resistance mutations in the bacterial ribosomal protein L16, which is shown to be homologous to archaeal protein L10e, cluster to the same region as the rRNA mutations. The Evn-binding site overlaps with the binding site of initiation factor 2. Evn inhibits activity of initiation factor 2 in vitro, suggesting that the drug interferes with formation of the 70S initiation complex. The site of Evn binding and its mode of action are distinct from other ribosome-targeted antibiotics. This antibiotic target site can potentially be used for the development of new antibacterial drugs.
引用
收藏
页码:3726 / 3731
页数:6
相关论文
共 50 条
[1]   Presence of variations in ribosomal protein L16 corresponding to susceptibility of enterococci to oligosaccharides (avilamycin and evernimicin) [J].
Aarestrup, FM ;
Jensen, LB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3425-3427
[2]   Evernimicin (SCH27899) inhibits a novel ribosome target site: Analysis of 23S ribosomal DNA mutants [J].
Adrian, PV ;
Mendrick, C ;
Loebenberg, D ;
McNicholas, P ;
Shaw, KJ ;
Klugman, KP ;
Hare, RS ;
Black, TA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3101-3106
[3]   Mutations in ribosomal protein L16 conferring reduced susceptibility to evernimicin (SCH27899): Implications for mechanism of action [J].
Adrian, PV ;
Zhao, WJ ;
Black, TA ;
Shaw, KJ ;
Hare, RS ;
Klugman, KP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :732-738
[4]   The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution [J].
Ban, N ;
Nissen, P ;
Hansen, J ;
Moore, PB ;
Steitz, TA .
SCIENCE, 2000, 289 (5481) :905-920
[5]   Evernimicin (SCH27899) inhibits both translation and 50S ribosomal subunit formation in Staphylococcus aureus cells [J].
Champney, WS ;
Tober, CL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1413-1417
[6]   TRANSFORMATION-METHODS FOR HALOPHILIC ARCHAEBACTERIA [J].
CLINE, SW ;
LAM, WL ;
CHARLEBOIS, RL ;
SCHALKWYK, LC ;
DOOLITTLE, WF .
CANADIAN JOURNAL OF MICROBIOLOGY, 1989, 35 (01) :148-152
[7]   Will avilamycin convert Ziracine into zerocine? [J].
Courvalin, P .
EMERGING INFECTIOUS DISEASES, 2000, 6 (05) :558-558
[8]  
Cundliffe E., 1981, MOL BASIS ANTIBIOTIC, V2nd, P402
[9]   FUNCTIONAL INTERACTIONS WITHIN 23S-RIBOSOMAL-RNA INVOLVING THE PEPTIDYLTRANSFERASE CENTER [J].
DOUTHWAITE, S .
JOURNAL OF BACTERIOLOGY, 1992, 174 (04) :1333-1338
[10]  
Garrett R. A., 1996, RIBOSOMAL RNA STRUCT, P327